TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study from University of Pittsburgh and UPMC researchers links pulmonary hypertension to changes in the cerebellum and frontal lobe, regions involved in memory, attention and planning. The findings connect those changes to inflammation and the NCOA7 gene, but the proposed biological marker is not yet established for clinical screening.
Researchers at the University of Pittsburgh and UPMC report that pulmonary hypertension is associated with specific brain tissue loss and weakened communication between regions involved in memory, attention and planning. Published in the Journal of Clinical Investigation on November 2, the study links those changes to inflammation involving the NCOA7 gene, offering a possible biological explanation for cognitive symptoms reported by some patients.
The team compared brain MRI scans from people with pulmonary hypertension with scans from people without the disease, drawing on a large public health database and a smaller group of UPMC patients. Both groups with pulmonary hypertension showed a consistent loss of brain tissue and weaker communication between the cerebellum, at the base of the brain, and the frontal lobe, behind the forehead. Those areas contribute to memory, attention and planning.
The researchers reported that the same pattern was absent in people with other heart, lung and psychiatric conditions included in their comparisons. They also said the differences could not be explained by low blood oxygen, impaired heart function or pulmonary hypertension medications. The findings suggest the brain changes may be linked specifically to the disease, rather than simply resulting from its effects on the heart and lungs.
Genetic analyses and laboratory studies tied the brain findings to a variant in NCOA7, a gene previously associated with inflammatory responses in pulmonary hypertension. Examination of cerebellum tissue from patients and mice found signs of overactive microglia, the brain’s immune cells, and changes in neurons. Mice with pulmonary hypertension that also lacked NCOA7 had more severe cerebellar damage than mice with the disease alone. The authors say this supports a causal role for the gene in regulating brain inflammation in the mouse model; it does not establish a screening test or treatment for people.
Why Brain Changes Matter in PH
Pulmonary hypertension raises blood pressure in the vessels carrying blood through the lungs. Its commonly reported symptoms include shortness of breath, chest pain and lightheadedness, while cognitive problems such as memory difficulties and impaired executive function can be less readily connected to the disease.
Current pulmonary hypertension management guidelines do not include cognitive screening, and the study authors say there is no established biological marker to predict or track the disease’s effects on the brain. The results raise the possibility that brain health should receive more attention in research and clinical discussions. They also point to inflammation as a potential research target, but the study does not show that treating inflammation will prevent cognitive decline or improve patients’ symptoms.
Because the findings identify brain changes in more than one patient group and connect them to a biological mechanism, they may help researchers investigate whether similar processes occur in other vascular or inflammatory conditions. That broader relevance remains a hypothesis, not a finding demonstrated across those diseases.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Levoit Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft²
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
As an affiliate, we earn on qualifying purchases.
How Researchers Traced NCOA7
The study grew from earlier work by senior researcher Stephen Chan, a University of Pittsburgh School of Medicine and UPMC physician-scientist. That research identified an NCOA7 variant that, according to the report, drives inflammatory responses in about one-quarter of pulmonary hypertension patients and is associated with worse survival odds.
Chan proposed that the variant might also be related to inflammation in the brain. The new research tested that idea using brain imaging, genetic data and laboratory studies. The journal paper, by Okawa and colleagues, is titled “Cerebellar and frontal lobe alterations in pulmonary hypertension implicate an inflammatory lung vascular/brain axis” and was published with DOI 10.1172/jci195110.
“This changes the way we look at a disease like pulmonary hypertension. In medicine, we typically treat the symptoms of one organ system; but the reality is that our bodies are very complex, and disease processes may be affecting multiple parts of the body in a variety of ways.”
— Stephen Chan, M.D., Ph.D., University of Pittsburgh and UPMC
Limits of the Current Evidence
The report does not establish how often the observed brain changes lead to measurable cognitive impairment, or whether the MRI findings predict how an individual patient’s symptoms will progress. It also does not provide evidence that the proposed NCOA7-related marker is ready for routine screening.
The results connect human patient data with laboratory findings, including a mouse model, but further work would be needed to determine whether the mechanism applies across a wider range of patients and disease stages. The authors’ suggestion that similar inflammation may contribute to dementia, aging or other conditions is a research hypothesis; this study does not test or confirm those broader links.
Testing Screening and Treatment Ideas
The study points to follow-up research on whether NCOA7-related measures can predict brain changes or cognitive symptoms in people with pulmonary hypertension. Researchers would also need to test whether cognitive screening can identify problems early enough to guide care, since current guidelines do not include it.
Another open research question is whether targeting inflammation can protect brain function. The present findings identify a possible biological pathway, but they do not demonstrate that an intervention works. For now, the immediate next step is further study to confirm the marker’s value and clarify how the brain findings relate to patients’ day-to-day cognition.
Key Questions
What did the study find about pulmonary hypertension and the brain?
Researchers reported brain tissue loss and weaker communication between the cerebellum and frontal lobe in pulmonary hypertension patient groups. These regions are involved in memory, attention and planning.
What role may NCOA7 play?
The study linked an NCOA7 variant to inflammation in the cerebellum. In mice with pulmonary hypertension, lacking the gene was associated with more severe cerebellar damage. The findings do not establish a human treatment based on NCOA7.
Does the study prove pulmonary hypertension causes cognitive decline?
The study reports brain changes associated with pulmonary hypertension and evidence of an inflammatory mechanism. It does not establish that every patient will develop cognitive impairment or determine how symptoms change over time.
Can doctors use an NCOA7 test to screen patients now?
No clinical screening test is established by this report. The researchers describe a possible biological marker, but its ability to predict or track cognitive effects needs further study.
Could the findings apply to dementia or aging?
Senior researcher Stephen Chan suggested the mechanism might be relevant to other inflammatory conditions, including some related to dementia and aging. That broader connection remains unconfirmed by this study.
Source: news-medical.net
